Phio Pharmaceuticals CORP Form 4 insider transactions
NASDAQ
Phio Pharmaceuticals Corp. Director Robert L. Ferrara has acquired 2,500 shares of common stock at $2.4199 per share, increasing his total beneficial ownership to 15,666 shares.
NASDAQ
Phio Pharmaceuticals Corp.'s Chairman, President, and CEO, Robert J. Bitterman, acquired 1,500 shares of common stock at $2.75 per share, increasing his beneficial ownership to 25,149 shares.
NASDAQ
Robert Bitterman, Chairman, President, and CEO of Phio Pharmaceuticals Corp., recently purchased additional shares of the company's common stock.
NASDAQ
Robert L. Ferrara, a director of Phio Pharmaceuticals Corp., purchased 2,500 shares of common stock at a weighted average price of $1.82 on May 20, 2025.
NASDAQ
Form 4: Phio Pharmaceuticals VP, CFO Robert Infarinato Reports Acquisition and Disposal of Common Stock
Robert M. Infarinato, VP and CFO of Phio Pharmaceuticals Corp., reports acquiring 3,000 shares of common stock and disposing of 11,000 shares.
NASDAQ
Director Jonathan E. Freeman acquired 1,000 shares of Phio Pharmaceuticals Corp. through the vesting of a restricted stock unit on September 11, 2024.
NASDAQ
Robert J. Bitterman, Chairman, President, and CEO of Phio Pharmaceuticals Corp., acquired 15,500 shares of common stock through the vesting of a restricted stock unit on September 11, 2024.
NASDAQ
Director Curtis Lockshin acquired 2,000 shares of Phio Pharmaceuticals Corp. common stock on September 11, 2024, through a restricted stock unit grant.
NASDAQ
Robert L. Ferrara, a director of Phio Pharmaceuticals Corp., acquired 10,000 shares of common stock on September 11, 2024, through a restricted stock unit grant.
NASDAQ
Patricia A. Bradford, a director of Phio Pharmaceuticals Corp., acquired 8,000 shares of common stock on September 11, 2024, through a restricted stock unit grant.
NASDAQ
Robert M. Infarinato, CFO of Phio Pharmaceuticals, reports the acquisition of 8,000 shares of common stock on August 13, 2024.
NASDAQ
Robert J. Bitterman, President and CEO of Phio Pharmaceuticals Corp., purchased 1,000 shares of common stock at $0.74 per share on June 7, 2024.
NASDAQ
Robert J. Bitterman, President & CEO of Phio Pharmaceuticals Corp., purchased 1,000 shares of common stock at $0.75 per share on June 6, 2024.
NASDAQ
Caitlin Kontulis, Secretary & VP Finance & Admin of Phio Pharmaceuticals Corp., reports the withholding of shares to cover tax obligations related to vesting restricted stock units.
NASDAQ
Robert Bitterman, President & CEO of Phio Pharmaceuticals Corp., recently purchased 2,500 shares of common stock at $0.91 per share, increasing his total holdings.